Avalyn Pharma Inc. Total Liabilities and Equity
Avalyn Pharma Inc. (AVLN) had Total Liabilities and Equity of $425.45 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-12
- 2026-06-30: Liabilities and Equity $425.45M.
- 2026-03-31: Liabilities and Equity $135.66M.
- 2025-12-31: Liabilities and Equity $148.88M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $425.45M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $135.66M 10-Q · filed 2026-06-03 |
| 2025-12-31 | $148.88M 10-Q · filed 2026-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B |